Trial Profile
Phase II Trial of Durvalumab (Medi4736) Plus Tremelimumab With Concurrent Radiotherapy in Patients With Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms IMMUNOPRESERVE-SOGUG; INMUNOPRESERVE; SOGUG
- 08 Jun 2021 Results assessing efficacy and safety of durvalumab plus tremelimumab with concurrent radiotherapy in patients with localized muscle invasive bladder cancer, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 05 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 31 May 2020 According to trial design presented at the 56th Annual Meeting of the American Society of Clinical Oncology, second stage accrual began in December 2019.